Workflow
ST吉药(300108) - 2024 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2024 was ¥333,330,280.33, a decrease of 3.69% compared to ¥346,106,530.05 in 2023[21] - The net profit attributable to shareholders for 2024 was a loss of ¥439,433,948.13, representing a 25.80% increase in losses from ¥349,309,644.16 in 2023[21] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥410,060,141.00, which is 41.51% worse than the loss of ¥289,768,468.85 in 2023[21] - The total profit for the period was -¥625,067,615.87, representing a decline of 41.30% year-over-year[41] - The net profit attributable to shareholders was -¥439,433,948.13, down 25.80% from the same period last year[41] - The company reported a net loss of ¥445.91 million for the year 2023, with equity attributable to shareholders of the parent company at -¥280.67 million[137] - The company has faced significant financial deterioration, with negative net profits for several consecutive years[137] - As of December 31, 2023, the company's total equity was -¥807.13 million, indicating ongoing financial instability[137] Assets and Liabilities - The total assets at the end of 2024 were ¥1,444,512,507.38, a decrease of 24.52% from ¥1,913,801,546.81 at the end of 2023[21] - The company's net assets attributable to shareholders at the end of 2024 were negative at ¥-776,519,451.36, a decline of 176.66% from ¥-280,671,891.27 at the end of 2023[21] - The company reported total assets of 1.445 billion and total liabilities of 2.948 billion, resulting in a debt-to-asset ratio of 204.08%[74] - Short-term borrowings amounted to 612,096,046 yuan, representing 42.37% of total liabilities, an increase from 38.01%[60] - Long-term borrowings were recorded at 676,059,729.74 yuan, which is 46.80% of total liabilities, up from 35.34%[60] Cash Flow - The cash flow from operating activities for 2024 was a net outflow of ¥36,031,399.80, which is 7.44% worse than the outflow of ¥33,535,035.85 in 2023[21] - Cash inflow from operating activities decreased by 9.64% to ¥265,549,005.63, while cash outflow decreased by 7.89% to ¥301,580,405.43[54] - Net cash flow from investment activities improved by 65.21%, primarily due to increased cash from investment income[54] - Cash flow from financing activities decreased by 32.77% to ¥45,369,606.28, attributed to reduced cash from borrowings[54][55] Legal and Compliance Issues - The audit report for 2024 issued by Beijing Dehao International CPA indicates an inability to express an opinion, highlighting significant risks to the company's ability to continue as a going concern[5] - The company faced severe liquidity issues, leading to overdue loans and multiple lawsuits, which significantly impacted its operations[5] - The company is facing multiple lawsuits due to overdue debts, leading to the freezing of several bank accounts and assets, which may result in judicial auctions of shares[75] - The company is currently in litigation with multiple parties, including Guoyao Holdings and Zhongmin Investment, with ongoing cases in Shanghai and Jilin[152] - The company is actively managing its legal risks and has engaged in mediation to resolve disputes amicably[152] Business Operations and Strategy - The company is engaged in the pharmaceutical industry, focusing on the production of traditional Chinese medicine and modern pharmaceuticals[31] - The pharmaceutical sector is increasingly important due to the growing demand driven by an aging population and rising healthcare needs[30] - The company is focusing on developing new products, including a low oil absorption white carbon black to meet customer needs and enhance market competitiveness[52][53] - The company is actively involved in the sale of health foods and cosmetics, diversifying its revenue streams[70] - The company is focusing on research and development in fine chemical products and silicon materials, aiming to enhance its product offerings[71] Shareholder and Governance - The company has a board of 5 directors, including 2 independent directors, complying with legal and regulatory requirements[85] - The company has a supervisory board consisting of 3 supervisors, including 1 employee representative, also in compliance with legal and regulatory requirements[86] - The total remuneration paid to the board of directors, supervisors, and senior management in 2024 amounted to 4.2577 million CNY[105] - The company has established a performance evaluation and incentive mechanism linking management compensation to operational performance and key management indicators[85] - The company ensures strict compliance with information disclosure regulations, providing timely and accurate information to stakeholders[86] Future Outlook - The company has outlined a future outlook with a projected revenue growth target of 36.93% for the upcoming fiscal year[93] - The company plans to enhance its research and development efforts, focusing on innovative solutions to meet market demands[93] - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence, targeting a completion date by Q4 2025[101] - The company plans to enhance its digital marketing efforts, aiming for a 30% increase in online sales channels by the end of 2025[101] Employee and Training - The total number of employees at the end of the reporting period is 900, with 471 in production, 135 in sales, 90 in technical roles, 28 in finance, and 176 in administration[115] - The company conducts weekly training sessions for employees on production skills and safety knowledge[116] Environmental and Social Responsibility - The company emphasizes environmental protection and social responsibility in its operations, aiming for a balance between economic and social benefits[130] - The company respects and protects the rights of stakeholders, balancing the interests of shareholders, employees, and society[86]